Background 22q11.2 deletion syndrome (22q11DS) is a common microdeletion syndrome associated with a variety of negative health, cognitive, emotional, and behavioral outcomes. 22q11DS is comorbid with many psychiatric disorders including attention-deficit/hyperactivity disorder (ADHD). The current study aimed to investigate the cognitive, behavioral, and functional outcomes that a childhood ADHD diagnosis predicts to in adulthood. Methods This longitudinal study followed 52 individuals with 22q11DS over 9 years. Childhood ADHD was operationalized both categorically (Diagnostic and statistical manual -4th edition (DSM-IV) ADHD diagnoses) and dimensionally (inattentive and hyperactive-impulsive symptoms) and was tested as predictors of young adult outcomes. Results As young adults, children with 22q11DS þ baseline ADHD had more parent-reported executive dysfunction and lower levels of clinician-rated overall functioning than those with 22q11DS yet without ADHD. Dimensional symptoms of ADHD in childhood did not predict young adult outcomes. No self-report differences emerged between those with and without baseline ADHD. The majority (82.4%) of individuals with 22q11DS þ baseline ADHD were never treated with an ADHD medication. Conclusions A categorical diagnosis of ADHD in childhood predicted a greater variety of worse outcomes than dimensional levels of ADHD symptoms. Despite the significant impact of comorbid ADHD in 22q11DS, evidence-based treatment rates were low.
22q11.2 deletion syndrome (22q11DS), also known as velo-cardio-facial syndrome, is the most common identified microdeletion syndrome and is caused by an interstitial deletion from chromosome at the 22q11.2 band. In most cases, 22q11DS is caused by a deletion of 3 million base pairs of DNA encompassing 40-50 genes. The majority (90%) of 22q11.2 deletions are de novo (Shprintzen et al., 2005) . 22q11DS is relatively common, occurring in $1:5,950 births (Botto et al., 2003) . Heart malformations and cleft palate are common characteristics of 22q11DS; yet, not all individuals demonstrate either (Shprintzen, 2000) . Many individuals with 22q11DS have cognitive impairments, with IQs generally 1-2 SDs below the mean for age (Antshel et al., 2007) . While a specific mechanism has not been definitively identified, several of the genes that are deleted on one copy of chromosome 22q11.2 are thought to contribute to cognitive impairments observed in 22q11DS (Philip & Bassett, 2011) .
In addition to cognitive impairments, 22q11DS is associated with a variety of psychiatric comorbidities. Attention-deficit/hyperactivity disorder (ADHD), major depressive disorder, anxiety disorders, oppositional defiant disorder, and autism spectrum disorder are all comorbid with 22q11DS (Schneider et al., 2014) . Further, individuals with 22q11DS are at increased risk for psychiatric comorbidities in adulthood, in particular schizophrenia (Schneider et al., 2014) . These psychiatric comorbidities likely present challenges for individuals with 22q11DS and their families beyond what is imparted by 22q11DS, although this research question has not been systematically studied (Schneider et al., 2014) .
Attention-Deficit/Hyperactivity Disorder
ADHD is one of the most prevalent comorbid disorders in individuals with 22q11DS (Schneider et al., 2014) . Approximately 4-12% of children without 22q11DS are diagnosed with ADHD (Spencer, Biederman, & Mick, 2007) . The prevalence rate of ADHD in 22q11DS is roughly 5-fold higher (30-40%) than the prevalence rate of ADHD in the general population (Schneider et al., 2014) . In non-22q11DS cross-sectional samples, ADHD negatively affects academic, occupational, social, and emotional functioning (de Schipper et al., 2015) . Longitudinally, children with ADHD are at greater risk for difficulties in late adolescence and early adulthood, including school failure, emotional difficulties, dysfunctional relationships, legal problems, substance abuse, and occupational difficulties . Thus, an ADHD diagnosis is a concern both in childhood and young adulthood.
In the only longitudinal study to date that has investigated ADHD in 22q11DS, Antshel and colleagues (2013) followed children with 22q11DS both with and without ADHD into adolescence. The developmental trajectories of those with 22q11DS were compared with control children with ADHD. Results indicated that children with 22q11DS and ADHD (22q11DS þ ADHD) experienced largely similar longitudinal trajectories to control children with ADHD. Hyperactivity-impulsivity symptoms in the 22q11DS þ ADHD group, however, increased over time, a finding contrary to the literature on idiopathic ADHD . The developmental delays in the 22q11DS and ADHD group and the low pharmacotherapy use in the 22q11DS population may explain this finding (Tang et al., 2014) .
Individuals with 22q11DS þ ADHD were at increased risk for oppositional defiant disorder, at similar rates to those with idiopathic ADHD, both of which are higher than individuals with 22q11DS only (Antshel et al., 2013) . However, mood and anxiety disorders were no more prevalent in 22q11DS þ ADHD than in individuals with 22q11DS only (Antshel et al., 2013) , contrary to idiopathic ADHD research . Similar to idiopathic ADHD (Hurtig et al., 2007) , major depression predicted ADHD persistence in the 22q11DS population (Antshel et al., 2013) . Overall, this study provided evidence that childhood factors that predict ADHD persistence in non-22q11DS populations predict persistence in individuals with 22q11DS, with few exceptions. Presently, the Antshel and colleagues study is the only study that has considered the longitudinal course of children with 22q11DS þ ADHD. This study is limited principally by the short follow-up period (3 years).
Need for Current Study
The persistence of ADHD into adulthood has been empirically supported, both dimensionally along a continuum representing elevated symptoms and as a categorical diagnosis (ADHD vs. non-ADHD) (Faraone et al., 2015) . Nevertheless, the developmental trajectories for children with ADHD are heterogeneous . Efforts to understand developmental trajectories are needed, especially in populations of children with ADHD and an additional childhood developmental disorder (like 22q11DS). ADHD is frequently comorbid with other childhood developmental disorders besides 22q11DS .
Investigating adult outcomes of childhood ADHD in developmentally delayed populations is important for several reasons. First, this information can be clinically useful and provide guidance about longitudinal outcomes for clinicians and parents. For example, ADHD is comorbid with a variety of other genetic, medical, and neurodevelopmental conditions, including fragile X syndrome, Williams syndrome, and Klinefelter syndrome (Lo-Castro, D'Agati, & Curatolo, 2011) . However, we know little about the longitudinal course of ADHD in 22q11DS. Second, lower intelligence predicts ADHD persistence and impairments in adulthood (Faraone et al., 2015) ; yet, most studies on ADHD exclude those with an IQ <80 (Mackenzie & Wonders, 2016) . Thus, we do not know the longitudinal outcomes of individuals with ADHD who have IQs <80. Third, given that many youth with developmental delays are inattentive and restless (Lo-Castro et al. 2011) , there is risk for both overdiagnosis and underdiagnosis of ADHD in these children (Antshel, Phillips, Gordon, Barkley, & Faraone, 2006) . Following children with ADHD and developmental delays longitudinally would ultimately inform clinical practice by elucidating the extent to which a childhood ADHD diagnosis is a meaningful predictor of adult outcomes. Antshel and colleagues' (2013) examination of the longitudinal course of ADHD in the 22q11DS population suggests that childhood ADHD in 22q11DS is of concern into adolescence, but the functional consequences of childhood ADHD into young adulthood are, as of yet, unknown. Rather than focus on ADHD diagnostic continuity from childhood into adulthood, this study investigated whether behavioral and functional outcomes would worsen over time for children with 22q11DS and ADHD. Based on the idiopathic ADHD literature, we hypothesized that a childhood ADHD diagnosis in 22q11DS (22q11DS þ baseline ADHD) would predict to poorer behavioral and functional outcomes in young adulthood compared with those with 22q11DS, yet no ADHD (22q11DS only) even after controlling for childhood levels of these variables. Aim 1 tested this hypothesis by examining whether a categorical diagnosis of childhood ADHD predicted behavioral and functional outcomes in adulthood for children with 22q11DS. Given the controversies about ADHD diagnoses in individuals with developmental disorders (Antshel et al., 2006) , Aim 2 tested this hypothesis by examining whether continuous, dimensional measures of childhood ADHD symptoms (i.e., inattentive, hyperactive-impulsive symptoms) predicted behavioral and functional outcomes in adulthood. Others (Neely, Green, Sciberras, Hazell, & Anderson, 2016) have suggested that using both categorical and dimensional approaches is particularly important for youth with neurodevelopmental disorders.
Method

Participants
This 9-year longitudinal study followed individuals with 22q11DS every 3 years; thus, four time points (baseline, Year 3, Year 6, and Year 9) were included in the larger study. Children with 22q11DS were initially recruited from a large academic medical center in the northeastern United States during the years [2002] [2003] [2004] [2005] . All families that met inclusion criteria agreed to participate. Only those children with a fluorescence in situ hybridization-confirmed deletion of 22q11.2 were included. Children with an identifiable genetic disorder (other than 22q11DS) or children with an identifiable neurological condition (e.g., traumatic brain injury, preterm birth) that is known to affect cognitive or psychiatric function were excluded from participation. For the current project, only participants who had Time 4 (young adult) data and who also had baseline data were included. Our total sample consisted of 52 children with 22q11DS (28 males). At baseline, the average age of individuals with 22q11DS was 12.2 years (SD ¼ 2.3), and at Time 4, the average age of 22q11DS participants was 21.3 years (SD ¼ 2.2).
Sample Representativeness
Given that we imposed strict participation criteria (requiring both baseline and Time 4 data), not all participants in the larger study are included in our analyses. Thus, we compared our study subsample with all individuals who participated at baseline: participants in the current study did not differ on any relevant Time 1 sociodemographic measures, including participant age
. Likewise, participants in the current project did not differ from those from the larger project on any relevant social and cognitive measures, including baseline adaptive functioning
. Thus, the current study participants appear to be representative of the larger project sample.
ADHD Status
At baseline (childhood), 23 of the 52 individuals with 22q11DS met formal Diagnostic and statistical manual -4th edition (DSM-IV) diagnostic criteria for ADHD based on a structured psychiatric interview with the participants' parents. This prevalence rate (44%) is similar to what others have reported in the literature (Schneider et al., 2014) . Sex differences between the two 22q11DS groups approached significance, X 2 (1) ¼ 3.68, p ¼ .055 in that more males were diagnosed with ADHD. Age differences existed between the two 22q11DS groups at both baseline, F(1, 51) ¼ 4.00, p ¼ .050, and young adulthood, F(1, 51) ¼ 4.13, p ¼ .047. At both periods, participants with 22q11DS þ baseline ADHD were slightly younger than those with 22q11DS only. Given the age differences between the two 22q11DS groups, analyses comparing the two 22q11DS groups will control for the effects of age. Please see Table I for descriptive data.
For the purposes of this study, we considered ADHD treatment status as positive if, at any point during the 9-year study, a parent reported that the individual with 22q11DS was prescribed an FDAapproved ADHD medication. The majority (82.4%) of individuals with 22q11DS þ baseline ADHD were never treated with an FDA-approved ADHD medication.
ADHD Status and Attrition
Longitudinal retention rates are presented in Supplementary Figure S1 for both the 22q11DS-only and 22q11DS þ baseline ADHD groups. A chi-square analysis indicated that there was not differential rates of attrition between the two groups, X 2 (1) ¼ .89, p ¼ .345.
Measures ADHD was assessed categorically via the childhood Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL) (Kaufman et al., 1997) . A child and adolescent psychiatrist or clinical child psychologist administered the KSADS. Based on 12 videotaped interviews that were rated by both administrators, the kappa coefficient was .91, signifying good interrater reliability. ADHD symptoms were assessed dimensionally in childhood using the Behavior Assessment System for Children-Parent Rating Scale (BASC-PRS) (Reynolds & Kamphaus, 1992) .
Our young adult outcome variables were chosen a priori based on the idiopathic ADHD literature, which emphasizes that children with ADHD often lose their diagnosis in adulthood, yet remain symptomatic and impaired (Faraone, Biederman, & Mick, 2005) .
Parent Report Measures Time 1 BASC-PRS
The BASC-PRS (Reynolds & Kamphaus, 1992 ) is a measure of parent-reported behaviors of children and adolescents rated on a four-point frequency scale from "Never" to "Almost always." Responses are organized into nine clinical scales (Aggression, Anxiety, Attention Problems, Atypicality, Conduct Problems, Depression, Hyperactivity, Somatization, and Withdrawal), five adaptive behavior scales, and seven content scales. For the current study, only the Hyperactivity and Attention Problems scales were used. Item raw scores are transformed into T-scores (M ¼ 50, SD ¼ 10), with higher scores indicating more maladaptive behaviors.
Time 4 Vineland Adaptive Behavior Scales, Second Edition, Composite Score
The Vineland Adaptive Behavior Scales-2nd edition (VABS-II) (Sparrow, Cicchetti, & Balla, 2005 ) Parent/ Caregiver Rating Form is a 297-item questionnaire rated on a three-point scale: 2 (usually), 1 (sometimes or partially), 0 (never), for which parents were asked to rate their adult child's ability to independently perform behaviors across three skill domains: Communication, Daily Living, and Socialization. Standard scores (M ¼ 100, SD ¼ 15) are provided for each domain and a Total Composite, with higher scores indicating better functioning. For the current study, only the VABS-II Total Composite was used.
Time 4 Behavior Rating Inventory of Executive Functioning-Adult Version
The Behavior Rating Inventory of Executive Functioning-Adult (BRIEF-A) informant version (Roth, Isquith, & Gioia, 2006 ) is an standardized parent-report measure that assesses a collateral reporters' view of an adults' executive functioning in their everyday environment. The BRIEF-A contains 75 equivalently items that load onto nine subdomains. The Global Executive Composite (GEC) index represents the overall EF score and was used in this study. The GEC comprises items for emotional control, shifting, inhibition, self-and task monitoring, planning/organization, working memory, and initiation scales. Higher scores indicate less well-developed executive functioning skills.
Clinician-Rated Measures Time 4 Global Assessment of Functioning
The Global Assessment of Functioning (GAF) (APA, 2000) is a clinician-rated global measure of functioning ranging from 0 to 100. Clinicians use the GAF to subjectively rate patients on their social, academic, occupational, and psychological functioning, with higher scores representing better functioning.
Time 4 Premorbid Adjustment Scale, Total Score The Premorbid Adjustment Scale (PAS) (CannonSpoor, Potkin, & Wyatt, 1982 ) is an interview-based, clinician-rated instrument used to assess functioning. The Total PAS score incorporates items pertaining to sociability, withdrawal, peer relationships, education, employment, establishment of independence, socialpersonal adjustment, degree of interest in life, and global assessment of highest level of functioning achieved thus far. These items contribute to the adulthood PAS Total score. Clinician ratings on PAS are scored on a 0-6 Likert scale, with 0 indicating typical adjustment and 6 indicating severe impairment. For the current study, only the adulthood PAS Total score was used.
Self-Report Measures Time 4 BRIEF-A
The BRIEF-A self-report version (Roth et al., 2006) was used to assess self-report of executive functioning in his/her everyday environment. Please see above for description of the BRIEF-A. The decision to administer both parent and self-report versions of the BRIEF-A is supported by the moderate association noted between parent-and self-report of global executive functioning (r ¼ .34) and the stronger associations in the 22q11DS-only group (r ¼ .52) relative to the 22q11DS þ baseline ADHD group (r ¼ .16). For the current study, only the BRIEF-A self-report GEC index was used.
Time 4 Adult Self-Report
The Adult Self-Report (ASR) (Achenbach & Rescorla, 2003) scale was used to assess the young adults with 22q11DSs' opinions of their symptoms and functioning. The ASR consists of 123 statements that the adult indicates whether the behavior is not true, somewhat or sometimes true, or very or often true. These statements then load onto eight scales. Raw scores are transformed into T-scores for results interpretation. For the current study, only the Internalizing and Externalizing Composite T-scores were used.
Time 4 Social Adjustment Scale-Self-Report
The Social Adjustment Scale-Self-Report (SAS-SR) (Weissman, 1999 ) is a 54-item self-report scale that measures adjustment in social role areas: work, social, and leisure activities; relationships with extended family; and role as a spouse or partner, parental role, and role within the family unit. Mean scores are transformed into T-scores, whereby higher scores indicate more social impairment. For the current study, only the SAS-SR Total was used.
Procedures
Informed consent and assent were attained from parents and participants. At all four periods, a doctoral-level examiner administered all psychological tests to participants in a quiet room. Parents completed all parent-report rating scales in a separate room. The same measures were administered to all participants and their parents.
Planned Analyses
To investigate Aim 1 (categorical childhood ADHD diagnoses predict poorer young adult outcomes), and reduce Type 1 error rates, two omnibus multivariate analyses of covariance (MANCOVA) of young adult variables were used with ADHD as the independent variable. One MANCOVA used self-reports (SAS-SR, BRIEF-A, ASR) of young adult outcomes as dependent variables, and age as a covariate. A second MANCOVA used parent/clinician reports (BRIEF-A, VABS-II, PAS, GAF) of young adult outcomes as dependent variables, and age and available baseline parent/clinician reports as covariates. To investigate Aim 2 (dimensional ADHD symptoms predict to poorer outcomes in adulthood), stepwise regression analyses were computed entering baseline levels of the self and parent/clinician-report outcome variables in Step 1. In
Step 2, parent report of child hyperactivity-impulsivity and inattention were entered simultaneously.
Statistical Power
Based on previous research on 22q11DS and ADHD (Antshel et al., 2013) , we predicted moderate effect size differences for young adult outcomes between individuals with 22q11DS with and without childhood ADHD (Aim 1). Assuming 80% power to detect differences, two groups, two repetitions of the four repeated measures, a correlation across repeated measures of .3, and an alpha level of .05, a sample size of 46 was needed to attain adequate statistical power for our self-report MANCOVA. For the parent/clinicianreport MANCOVA, a sample size of 59 was needed, because of the two repetitions of the six repeated measures. Thus, our Aim 1 self-report report analyses are adequately powered, whereas our parent/clinician analyses are slightly underpowered. Based on the extant ADHD research, which indicates childhood ADHD symptom severity levels are a predictor of adult outcomes with large effect sizes (Lara et al., 2009 ), we predicted a large effect size for our Aim 2 analyses. Assuming 80% power to detect differences, two predictors, and an alpha level of .05, a sample size of 42 was needed to attain adequate statistical power. Thus, our Aim 2 analyses are adequately powered.
Results
Aim 1-Categorical ADHD Diagnoses in Childhood
Young Adult ASR On the ASR, SAS-SR, and BRIEF-A, after controlling for age, no differences emerged between the young adults with 22q11DS þ baseline ADHD and those with 22q11DS only, Wilks k ¼ 0.81, F(6, 44) ¼ 1.77, p ¼ .126, g 2 ¼ .195. As noted in Table I , no differences emerged as a function of ADHD status.
Parent/Clinician Reports
After controlling for age and Time 1 variables as covariates, differences emerged between the two groups on parent/clinician report variables, Wilks k ¼ .75, F(4, 46) ¼ 2.90, p ¼ .036, g 2 ¼ .249. As noted in Table I , the BRIEF-A GEC parent report and PAS Total clinician report variables differed as a function of ADHD status. In both the parent and clinician report variables, those with 22q11DS þ baseline ADHD were rated as functioning less well in young adulthood. Participants with 22q11DS þ baseline ADHD did not differ at follow-up from those without baseline ADHD in adaptive functioning based on the parent report VABS-II or the clinician-rated GAF. See Table I 2 ¼ .582. After controlling for baseline BRIEF GEC scores, BASC parent report of hyperactivity-impulsivity and inattention did not predict BRIEF-A GEC ratings in young adults with 22q11DS, F(2, 45)
Clinician-rated childhood GAF ratings predicted young adult GAF ratings, F(1, 47) ¼ 5.13, p ¼ .028, R 2 ¼ .100. After controlling for baseline GAF scores, parent report of childhood hyperactivity-impulsivity and inattention did not predict young adult GAF scores, F(2, 45) ¼ .22, p ¼ .801, R 2 change ¼ .009. Finally, childhood PAS Total ratings predicted young adult PAS Total ratings, F(1, 47) ¼ 3.40, p ¼ .047, R 2 ¼ .091. After controlling for baseline PAS Total scores, parent report of childhood hyperactivity-impulsivity and inattention did not predict young adult PAS Total scores, F(2, 45) ¼ 1.55, p ¼ .353, R 2 change ¼ .015. See Table II for relationships between parent, clinicians, and self-report of young adult outcome variables and parent-rated childhood hyperactivity-impulsivity and inattention.
Discussion
To our knowledge, this is the first study to use a longitudinal design to predict young adult outcomes in children with 22q11DS þ baseline ADHD. Our childhood ADHD prevalence rate (44%) is consistent with what others have reported in 22q11DS (Schneider et al., 2014) .
Categorical and Dimensional ADHD After controlling for baseline parent report of executive dysfunction, parents of youth with 22q11DS þ baseline ADHD reported that their young adult child had more executive dysfunction than did parents of young adults with 22q11DS only. Likewise, clinicians rated young adults with 22q11DS þ baseline ADHD as having lower levels of overall functioning in young adulthood after controlling for baseline functioning. In this way, differences between the two 22q11DS groups became more pronounced over time. No group differences emerged on any self-report data. When considering ADHD symptoms dimensionally, after controlling for baseline levels of variables, parent report of childhood ADHD symptoms did not predict any clinician or parent report variables of adult functioning. Similarly, parent report of childhood ADHD symptoms did not predict young ASR.
Others (Neely et al., 2016) have suggested that using both categorical and dimensional approaches to psychopathology is particularly important for youth with neurodevelopmental disorders. For predicting to young adult functional outcomes in 22q11DS, considering childhood ADHD as a categorical condition was a better predictor of young adult outcomes than a dimensional perspective. This finding argues against the notion that symptoms of inattention and hyperactivity-impulsivity are intrinsic to 22q11DS and therefore not worthy of further assessment or treatment. Our data suggest that such elevated symptoms, although common in individuals with 22q11DS (Ousley, Rockers, Dell, Coleman, & Cubells, 2007) , may reflect a diagnosis of ADHD. Moreover, impairment secondary to ADHD symptoms is a criterion in the Diagnostic and statistical manual -5th edition (DSM-5) (APA, 2013), and our data suggest that assigning a childhood ADHD diagnosis is meaningful and prognostic in youth with 22q11DS. If ADHD diagnoses were simply assigned to those with more severe ADHD symptoms, results in the dimensional analyses would have mirrored the categorical analyses. In contrast, a childhood diagnosis of ADHD (and not simply levels of ADHD symptoms in this population) was predictive of outcomes in 22q11DS.
Our data are also consistent with longitudinal research on idiopathic ADHD that suggests that childhood ADHD is associated with young adult outcomes including executive dysfunction and lower levels of functional independence (Barkley, Fischer, Smallish, & Fletcher, 2006) . Thus, our results of ADHD in the context of developmental delays mirror the idiopathic ADHD research results (which often exclude those with IQs < 80 from participation).
While two group differences emerged between the two 22q11DS groups in young adulthood, multiple young adult measures were not different between the two groups. Likewise, no self-report differences on any young adult variable emerged between the 22q11DS groups. Although some young adult outcomes are negatively affected by the presence of childhood ADHD, multiple other outcomes are not impacted significantly by ADHD. Rather, having developmental delays, as is common in 22q11DS (Antshel et al., 2007) , appears to be more impactful toward predicting young adult outcomes in some domains.
Parent and Young Adult Perceptions
Parent report and self-report of functioning were moderately associated with each other, yet were more strongly related in the 22q11DS-only group. Parents report more concerns about functioning than young adults with 22q11DS, both with and without ADHD. While parent and child reports of child functioning often differ (Kolko & Kazdin, 1993) , young adults with 22q11DS do not perceive themselves as experiencing difficulties when compared with their same aged peers. One possible explanation for this finding may be related to cognitive immaturity (Milich, 1994) . Cognitive immaturity has been forwarded as a hypothesis to explain the positive self-perceptions that exist in ADHD (Owens, Goldfine, Evangelista, Hoza, & Kaiser, 2007) . Our 22q11DS sample, both with and without ADHD, had mean IQs in the Borderline range for age. Thus, it is possible that developmental delays led to poor self-monitoring, which led to parents reporting lower functioning than self-report. However, others (Swanson, Owens, & Hinshaw, 2012 ) have encouraged researchers not to assume that parents are correct (and children are incorrect).
ADHD Treatment in 22q11DS
The majority of individuals with 22q11DS þ baseline ADHD were never treated with an FDA-approved ADHD medication. Our low ADHD treatment rates are consistent with previous evidence that suggests low treatment rates (between 60 and 80% are not treated) for 22q11DS and comorbid psychiatric disorders (not specific to ADHD) (Tang et al., 2014) . In 22q11DS, parents made decisions to not pursue an FDA-approved ADHD medication for their child with ADHD. There are likely a variety of reasons for these decisions. Future research, using a qualitative design, should investigate the pharmacotherapy decision-making processes for parents of youth with 22q11DS þ baseline ADHD. In conjunction with previous research that stimulant medication is safe and effective for use in individuals with 22q11DS (Gothelf et al., 2003) , these results indicate that the low rate of treatment in this population merits further consideration. Comorbid ADHD affects clinician and parent-report variables of adult functioning above and beyond the effects of developmental delays inherent to 22q11DS, yet may still be undertreated.
Limitations
While many of our analyses would not have survived a Bonferroni correction, our effect sizes are uniformly large, and we used MANCOVA designs (reducing the chance of type I error). Thus, we believe that these results likely represent the most robust differences between 22q11DS groups. Other real differences (with small to medium effect sizes) may exist, yet did not reach the p < .05 criterion. The lack of an IQ-matched control group is an additional limitation. Thus, the specificity of these results to 22q11DS þ baseline ADHD is not presently known.
Future Directions and Conclusion
Comorbid childhood ADHD as a categorical diagnosis is a significant predictor of parent report of executive dysfunction and clinician ratings of functioning 9-years later and predicted more young adult outcomes than considering childhood ADHD symptoms dimensionally. This suggests that DSM-5 Criterion D (impairment secondary to ADHD symptoms) is particularly important to consider in youth with developmental delays. Further research is needed to understand the mechanisms that may be responsible for these concerning long-term trajectories. Considering environmental factors (e.g., family, peer group) and the interaction of these factors with biological variables will likely prove most informative. Despite several significant negative long-term outcomes, most individuals with 22q11DS þ baseline ADHD were never treated with an FDA-approved medication. Given the low rate of pharmacological treatment for this population, despite some evidence for the efficacy (Gothelf et al., 2003) , future research should consider how best to increase the use of ADHD evidence-based interventions, both pharmacological and nonpharmacological, in 22q11DS.
In the idiopathic ADHD literature, parental lack of knowledge and misconceptions about ADHD and poor symptom recognition are barriers to treatment for children with ADHD (Bussing, Zima, Gary, & Garvan, 2003) . These barriers may also affect children with 22q11DS þ baseline ADHD. For example, low knowledge of ADHD and poor symptom recognition may exist in 22q11DS via diagnostic overshadowing. In diagnostic overshadowing, symptoms of one condition (ADHD) are ascribed to a secondary condition (22q11DS) (Jopp & Keys, 2001) . If a condition is not believed to exist or be valid, that condition is less likely to be treated (O'Brien, Kifuji, & Summergrad, 2006) . Further, parents of individuals with 22q11DS report concerns about cardiac effects and fear increased risk of psychosis as a function of stimulant use (Green et al., 2011) , despite some evidence to suggest that stimulant medication is safe and effective for use in this population (Gothelf et al., 2003) . Future research should consider the barriers for ADHD treatment in the 22q11DS population as well as how to address these barriers.
In summary, ADHD predicts several poor outcomes above and beyond the negative outcomes associated with 22q11DS. To the extent that ADHD remains undertreated and underresearched in 22q11DS, a significant portion of individuals with 22q11DS may endure several negative long-term outcomes that may be potentially modifiable with treatment.
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